With big bucks (and drugs) in hand, George Scangos' startup stakes out space in infectious diseases
Vir Biotechnology is going where Big Pharma has largely backed away — infectious diseases, such as HIV, hepatitis B and tuberculosis — and it's doing so with $600 million in backing from ARCH Venture Partners and others.
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Ron Leuty Source Type: news
More News: Biotechnology | Health Management | Hepatitis | Hepatitis B | Infectious Diseases | PET Scan | Pharmaceuticals | Tuberculosis